ROCKVILLE, MD., June 23 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protégé, the Company’s Phase 3 clinical study of teplizumab in type

ROCKVILLE , MD. , April 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent

ROCKVILLE , MD. , January 6 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical

Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics INGELHEIM, Germany and ROCKVILLE, MD, USA, October 26, 2010 -- Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global

ROCKVILLE, MD, October 26, 2010 -- MacroGenics, Inc, a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting

MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint ROCKVILLE, Md., INDIANAPOLIS, Ind. – Oct. 20, 2010 – MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protégé Data Monitoring Committee (DMC), composed of

ROCKVILLE, Md., July 15 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants

MacroGenics Appoints New Senior Vice President of Clinical Development ROCKVILLE , Md. , January 7 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment

ROCKVILLE , Md. , July 13, 2009 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the trea tment of individuals with suspected central nervous system infection due to West Nile

Paulo F. Costa Joins MacroGenics Board of Directors ROCKVILLE, MD., June 23, 2009 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis

Phase 3 PROTÉGÉ ENCORE Clinical Trial Initiated

MacroGenics Appoints New Vice President of Business Development ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric

Proceeds to be Used for Advancement of Cancer Stem Cells and Other Development Programs

Raven's Discovery Platform in Cancer Stem Cell Biology<br>Enhances MacroGenics' Oncology Capabilities and Complements Proprietary Antibody Technology Platforms

Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer Rockville, Maryland.   May 6, 2008.  MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the

Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments

Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman Rockville, MD.  September 26, 2007.  MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company’s Board of Directors.  With more than 20 years of experience in product development

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at MacroGenics

MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007 ROCKVILLE, MD.  July 9, 2007.  MacroGenics announced today that the companys investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody

JDRF Provides MacroGenics with $2 Million in Funding for "Prot&#233;g&#233;" Trial

MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors Rockville , Maryland.  October 16, 2006.   MacroGenics, Inc., a privately-held immunotherapeutics company, announced today that John Maraganore, Ph.D., President and CEO of Alnylam Pharmaceuticals, has joined the

Pivotal Trial of CD3 Monoclonal Antibody to Begin in 2006

Newly Published Data Validate CD32B as Key Target in Non-Hodgkins Lymphoma

MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs Rockville , Maryland, October 2, 2006  MacroGenics, Inc. announced today that the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of

MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it